Recent data suggest that inhaled corticosteroids reduce the number of clinical
exacerbations in chronic obstructive pulmonary disease (COPD). It remains unknown …

The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of
patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can …

Background The benefit harm profile of inhaled corticosteroids, and their effect on patient
oriented outcomes and comorbid pneumonia, osteoporosis and cardiovascular disease in …

Context Recent studies of inhaled corticosteroid (ICS) therapy for managing stable chronic
obstructive pulmonary disease (COPD) have yielded conflicting results regarding survival …

The role of inhaled corticosteroids (ICS) in asthma is well established, but their benefit in the
management of chronic obstructive pulmonary disease (COPD) is still controversial. The …

While the pharmacological management of chronic obstructive pulmonary disease (COPD)
has evolved from the drugs used to treat asthma, the treatment models are different and the …

Long-term treatment with inhaled corticosteroids (ICS) might attenuate lung function decline
and decrease airway inflammation in a subset of patients with chronic obstructive pulmonary …

Background It has been suggested that withdrawal of inhaled corticosteroids (ICS) in COPD
patients on maintenance treatment results in deterioration of symptoms, lung function and …

Background The role of inhaled corticosteroids (ICS) in chronic obstructive pulmonary
disease (COPD) has been the subject of much controversy. Major international guidelines …

Inhaled corticosteroids (ICS) reduce COPD exacerbation frequency and slow decline in
health related quality of life but have little effect on lung function, do not reduce mortality, and …